{"id":17289,"date":"2026-06-08T14:30:00","date_gmt":"2026-06-08T12:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=9f677bc559f239f8fdcde79b3a962882"},"modified":"2026-06-08T14:30:00","modified_gmt":"2026-06-08T12:30:00","slug":"interpath-global-expands-veterinary-focus-following-strong-growth-of-4cyte","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=17289","title":{"rendered":"Interpath Global Expands Veterinary Focus Following Strong Growth of 4CYTE\u2122"},"content":{"rendered":"

TORONTO, Ontario--(BUSINESS WIRE)--Interpath Global <\/a>is expanding its investment in veterinary education and industry engagement following the successful launch and continued growth of 4CYTE\u2122 Epiitalis\u00ae Forte Dog.<\/p><\/a><\/a>

\nOriginally developed to support joint health through Interpath\u2019s patented plant seed oil Epiitalis\u00ae, the 4CYTE\u2122 range has become one of Canada\u2019s most recognised joint health brands, trusted by veterinarians, clinics, and pet owners alike.<\/p>

\nWhile the brand has experienced strong organic growth over the past decade, Interpath is now increasing its focus on veterinary partnerships, education, and awareness initiatives across Canada.<\/p>

\n\u201cWe\u2019ve spent many years focused on research, product development, and delivering consistent outcomes in market,\u201d said Rebecca Britton, CEO of Interpath Global.<\/p>

\n\u201cWith the continued growth of 4CYTE\u2122 and increasing awareness around proactive joint health management, now is the right time for us to invest more heavily in supporting the veterinary profession through education, collaboration, and broader industry engagement.\u201d<\/p>

\nThe expansion comes as demand for joint health support continues to rise, particularly as pets live longer and owners seek proactive approaches to mobility and quality of life.<\/p>

\nUnlike many traditional joint supplements, 4CYTE\u2122 contains Epiitalis\u00ae, a patented plant seed oil ingredient developed through Interpath\u2019s long-term research program. The company says its focus remains on delivering evidence-backed products that support both veterinary recommendation and owner compliance.<\/p>

\nThe launch of 4CYTE\u2122 Epiitalis\u00ae Forte Dog last year has further strengthened the brand\u2019s position within the companion animal market, providing veterinarians and pet owners with an easy-to-administer daily gel format designed to support long-term use.<\/p>

\nAs part of its expanded veterinary strategy, Interpath will increase:<\/p>